Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

522 trials

NCT07726992
Recruiting
A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC
Phase 3 · China · 2 sites
Registry update: 8 Sept 2026
NCT07784387
Recruiting
A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal
Not applicable · Portugal · 1 site
Registry update: 28 Aug 2026
2025-524488-18-00
Recruiting
A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.
Phase 2 · Germany, Spain, France, Italy, Poland · 67 sites
Registry update: 21 Sept 2026
NCT07579195
Recruiting
Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
Phase 1/2 · United States · 1 site
Registry update: 25 Aug 2026
NCT07741448
Recruiting
Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC
Phase 2 · China · 10 sites
Registry update: 3 Aug 2026
NCT07341737
Recruiting
SL-28 for Advanced Solid Tumours
Phase 1/2 · Australia · 3 sites
Registry update: 15 Sept 2026
NCT07749924
Recruiting
Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC
Not applicable · China · 5 sites
Registry update: 9 Oct 2026
NCT07468851
Recruiting
A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy
Phase 1/2 · China · 2 sites
Registry update: 4 Sept 2026
NCT07848854
Recruiting
Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples
Phase 2 · China · 1 site
Registry update: 30 Sept 2026
NCT07749586
Recruiting
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Phase 1/2 · United States · 4 sites
Registry update: 13 Oct 2026
NCT07763197
Recruiting
Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)
Not applicable · United States · 1 site
Registry update: 13 Aug 2026
NCT06990061
Recruiting
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study
Not applicable · Belgium · 3 sites
Registry update: 11 Sept 2026
NCT07705035
Recruiting
DBC-664 in Adult Patients With Solid Tumors
Phase 1 · United States · 7 sites
Registry update: 27 Oct 2026
2026-525897-20-00
Recruiting
A study to check whether adding RUTI® to standard BCG treatment for high-risk early-stage bladder cancer is safe and how it changes the body’s defenses, with participants randomly receiving RUTI® or a look-alike treatment.
Phase 1 · Spain · 2 sites
Registry update: 18 Jun 2026
NCT07720284
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Phase 3 · Australia, Brazil, Canada, China, Germany, Spain, France, United Kingdom, India, Italy, Japan, South Korea, Poland, Thailand, Taiwan, United States · 136 sites
Registry update: 22 Jul 2026
NCT07638410
Recruiting
Prehabilitation in High-risk Oncologic Surgery
Not applicable · United States · 1 site
Registry update: 21 Sept 2026
NCT07518043
Recruiting
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
Phase 1 · China · 7 sites
Registry update: 27 Jul 2026
NCT07424287
Recruiting
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
Phase 3 · China · 2 sites
Registry update: 20 Jul 2026
NCT07762586
Recruiting
Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)
Phase 2 · United States · 1 site
Registry update: 13 Aug 2026
NCT07747740
Recruiting
Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
Phase 2 · Russia · 1 site
Registry update: 5 Aug 2026

Ordered by registry start date. Freshness and sponsorship never change the order.